Treatment of refractory metastatic breast cancer with 5-fluorouracil and levofolinic acid as 48 hours continuous venous infusion

Anticancer Research

Volumn 19, Issue 3 B, 1999, Pages 2289-2292

  Gebbia, Vittorio ^a,d   Mauceri, Gaetano ^a   Testa, Antonio ^b   Tirrito, Mariolina ^c   Varvara, Francesca ^b   Cucchiara, Anna ^b   Borsellino, Nicolo ^c   Girlando, Andrea ^a   Ferrara, Marcello ^a   Caruso, Francesco ^a  

^a Centro Catanese di Oncologia   (Italy)

^b Clinica Macchiarella   (Italy)

^c Clinica Torina   (Italy)

^d Centro Catanese di Oncologia   (Italy)

Author keywords

5 fluorouracil; Breast cancer; Levofolinic acid; Metastases; Vinorelbine

Indexed keywords

FLUOROURACIL; FOLINIC ACID; PYRIMIDINE ANTAGONIST;

ADULT; AGED; ANEMIA; ARTICLE; BONE METASTASIS; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTINUOUS INFUSION; DIARRHEA; DRUG RESPONSE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; NAUSEA; PHLEBITIS; PRIORITY JOURNAL; SKIN METASTASIS; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; LEUCOVORIN; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; SALVAGE THERAPY;

EID: 0032814918     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Smith G, Henderson IC: New treatments for breast cancer. Sem Oncol 23: 506-528 1 996.
2. Gianni L, Munzone E, Capri G et al: Paclitaxel by 3-hour infusion in combination with bolus doxonibicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13: 2688-2699, 1995.
3. Colucci G, Romito S, Gebbia V et al: Levofolinic acid 5-fluorouracil cyclophospahmide and escalating dosea of epirubicin with granulocyte colony-stimulating factor support ir, locally advanced anmd/or metastatic breast carcinoma: a phase I-II of the Southern Italy Oncology Group (GOIM). Br J Cancer 72: 1245-1250 1995.
4. Colucci G, Giotta F, Gebbia V et al: Dose intensification of mitoxantrone in combination with levofolinic acid fluorouraci cyclophosphdmide and granuclocyte colony stimulating factor support in advanced untreated breast cancer patients: a multicentric phase II study of the Suuthern Italy Oncology Group. Anticancer Drugs 8: 257-264, 1997.
5. Agostara B, Gebbia V, Testa A et al: Mitomcyn C and vinorelbine as second line chemotherapy for metastatic breast cancer. Tumori 80: 33-36, 1994.
6. Ferrero B, Gebbia V, Cannata G et al: Cisplatin and VP16 as salvage treatment for advanced breast carcinoma resistant or recurrent after first line chemotherapy for metastatic disease. Oncology Rep 2: 122-125, 1995.
7. Van Oosterom AT: Docetaxel (Taxotere): an effectivn agent in the mandgemernt of second-lire breast cavcer. Sem Oncol 22: 22-28, 1995.
8. Allegra CJ: Biochemical modulation: a modality that has come of therapeutic age. J Clin Oncol 9: 1723-1726, 1991.
9. Lockshin A, Danerberg A: Biohemical facturs affecting the tightness of 5 fluorodeoxyuridylate binding to human thymidylate synthetase. Biochem Pharmacol 30: 247-257, 1981.
10. Evans RM, Lakiri JD, Hakala MT et al: Effect of excess folate and deoxynosine on the activity and site of action of 5-fluurouraii. Gancer Res 41: 3288-3295, 1981.
11. Santi DV, Lakir JD, Hakala MT: Mechanim of intercation of thymidilate synthetase with 5-fluorodeoaxyridilate. Biochemistry 13: 471-480, 1974.
12. Swain SM, Lippmain ME, Eyail EF et al: Fluorouracil and hioh-dose leucovorin in previously treated patients with metastatic breast cancer. J Clin Oncol 7: 890-899, 1989.
13. Doroshow JH, Leorng L, Margeolin KF et al: Metastatic bredst cancer. Salvage therapy with fluorouicil and high-dose continuous-infusion leucovorin calcium. J Clin Oncol 7: 439-444, 1989.
14. Marini G, Simoncini E, Zaniboni A et al: 5-Fluoiouracil and high-dose folinic acid as salvage treatment of advanced breast cancer. An update. Oncology 44: 336-340, 1987.
15. Fine S, Erlichman C, Kaizer L et al: Phase II trial of 5-FU and folinic acid as first-line treatment for metastatic breast cancer. Proc Am Soc Clin Oncol 7: 41, 1988. Loprinzi CL: 5-Fluorouracil with leucovorin in breast cancer. Cancer 63: 1045-1047, 1989.
16. Fine S, Erlichman C, Kaizer L et al: Phase II trial of 5-FU and folinic acid as first-line treatment for metastatic breast cancer. Proc Am Soc Clin Oncol 7: 41, 1988. Loprinzi CL: 5-Fluorouracil with leucovorin in breast cancer. Cancer 63: 1045-1047, 1989.
17. Zaniboni A, Meriggi F, Arcangeli G et al: I-Foiinic acid and 5-fluorouracil in the treatment of advanced breasr cancer a phase II study. Ann Oncol 4 (suppl. 2): S41-S43 1993.
18. Lokich JJ, Ahigren JD, Gulio JJ et al: A prospecrive randomized comparison of continuous infusion fiuorouracil with conventional bolus schedule in metastatic colorectai carcinoma: a Mid Ariantic Oncology Program study. J Clin Oncol 7: 425-432, 1989.
19. Smith I: Continuous infusional 5-fluorouracil in breast cancer or rhe revivalof an old drug?. Ann Oncol 7: 771-772, 1996.
20. Wilke H, Laasen U, Achterrath W et al: Phdse I-II study with a weekly 24-hour infusion, of 5-fluorouracil plus high dose folinic acid (HD-FU/FA) in intensively pretreated patients with metastatic breast cancer. Ann Oncol 7: 55-58, 1996.
21. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47: 207-214, 1981.
22. Kaplan EL, Meier P: Non parametric estimation from incomplete observations. J Am Stat Assoc 55: 447-451, 1958.
23. Gebbia V, Borsellino N, Testa A et al: Treatment of refractory metastatic breast cancer with 5-fluorouracil plus levofolinic acid as continuous venous infusion: a phase II study. Anticancer Drugs 1998, in press.